Drug
Hydralazine and magnesium valproate
Hydralazine and magnesium valproate is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 32 (50.0%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_3
Hydralazine Valproate for Cervical Cancer
NCT00532818
unknownphase_3
Hydralazine Valproate for Ovarian Cancer
NCT00533299
completedphase_2
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
NCT00404508
completedphase_2
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
NCT00404326
Clinical Trials (4)
Showing 4 of 4 trials
NCT00532818Phase 3
Hydralazine Valproate for Cervical Cancer
NCT00533299Phase 3
Hydralazine Valproate for Ovarian Cancer
NCT00404508Phase 2
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
NCT00404326Phase 2
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4